Pruritus intensity, psoriasis severity often not correlated

Share this article:

Better targeted antipruritic therapies needed for patients with psoriasis.

Pruritus intensity does not correlate with psoriasis severity
Pruritus intensity does not correlate with psoriasis severity

Targeted antipruritic therapies are needed for patients with psoriasis and other dermatologic conditions, according to recent letter to the editor published in the Journal of American Academy of Dermatology.

Previous reports in the literature suggest an estimated 70% of patients with psoriasis have at least moderate pruritus and there are conflicting reports regarding a link between pruritus intensity and psoriasis disease severity. In addition, impact of topical corticosteroids and vitamin D analogs on pruritus in psoriasis has not been effectively studied.

David Roblin, MD, FRCP, from Creabilis Ltd. in the United Kingdom, and colleagues from Temple University, Philadelphia, reported on data for 157 patients with mild to moderate psoriasis based on the Investigator Global Assessment and a mean modified Psoriasis Area Severity Index (mPASI) score of 8.9.

Overall, 98 patients in the study had pruritus; 68.8% had at least moderate pruritus (visual analog scale [VAS] score ≥ 40 mm) and 33.8% severe pruritus (VAS score ≥ 70 mm).

Using these data, the researchers explored the potential relationship between pruritus, measured by VAS, and psoriasis disease severity, measured by mPASI. Based on the coefficient of determination (R2) value, only 3.8% of the variability in pruritus severity can be explained by its relationship to disease severity as measured by mPASI.

“As mPASI measures inflammatory-mediated aspects of psoriasis, this lack of correlation suggests that treating pruritus in patients with psoriasis with anti-inflammatory agents may be a suboptimal approach,” the study authors wrote. “The lack of correlation between pruritus severity and psoriasis disease severity that we have observed, coupled with the high prevalence of pruritus and unmet need, warrants greater attention to pruritus by clinicians and researchers to develop targeted antipruritic therapies for patients with psoriasis and other dermatologic conditions.”

References

  1. Roblin D. J Am Acad Dermatol. 2014;70(2):290-291.

Disclosure: This research was supported by Creabilis Ltd. Roblin is an employee of Creabilis Ltd.

Share this article:
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Psoriasis Information Center

Sign Up for Free e-newsletters

More in Psoriasis Information Center

Psoriatic arthritis outcomes worse with smoking

Psoriatic arthritis outcomes worse with smoking

Worse patient-reported outcomes, shorter treatment adherence, and poorer response to treatment among smokers.

Cardiovascular risk factors may dictate psoriatic arthritis severity

Cardiovascular risk factors may dictate psoriatic arthritis severity ...

Half of the patients in the study were newly diagnosed with four or more symptoms of metabolic syndrome.

Weight-loss benefits extend to psoriatic arthritis

Weight-loss benefits extend to psoriatic arthritis

Losing weight while taking biologics for psoriatic arthritis (PsA) resulted in greater symptom improvement among obese/overweight compared than no weight loss.